miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer

Estrogen receptor-α (ERα) is essential for estrogen-dependent growth and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα-positive breast cancer. Breast cancer patients show a wide range of ERα expression levels which change in individual patients during disease progression and in response to systemic therapies. However, little is known concerning how the expression of ERα is regulated in human breast cancer. Recently, several microRNAs (miRNAs) have been identified to regulate ERα expression and to predict ER, progesterone receptor (PR) and human epidermal growth factor 2 (HER2) status. The expression levels of miR-342 and ERα mRNA were analyzed in human breast cancer samples and cell lines by quantitative reverse transcription (RT)-PCR analysis. The correlations between the expression levels of miR-342 and clinicopathological factors were analyzed. Statistically significant associations were observed between miR-342 and ER, HER2 and vascular endothelial growth factor (VEGF) status in the human breast cancer samples and the levels of miR-342 gradually increased as ERα mRNA expression increased. Moreover, ectopic overexpression of miR-342 upregulated the expression levels of the ERα mRNA and significantly sensitized the MCF-7 cells to tamoxifen-induced apoptosis and inhibition of cellular proliferation. These results suggested that miR-342 expression is positively correlated with ERα mRNA expression in human breast cancer and that it may be a significant marker for predicting tamoxifen sensitivity in ERα-positive breast cancer and a potential target for restoring ERα expression and responding to antiestrogen therapy.

[1]  C. Croce,et al.  MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. , 2010, Journal of the National Cancer Institute.

[2]  D. Shapiro,et al.  Estrogen Receptor-dependent and Estrogen Receptor-independent Pathways for Tamoxifen and 4-Hydroxytamoxifen-induced Programmed Cell Death* , 2002, The Journal of Biological Chemistry.

[3]  N. Kondo,et al.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. , 2009, Cancer research.

[4]  H. Yamashita,et al.  Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer , 2006, Breast cancer.

[5]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[6]  B. White,et al.  The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-α (ERα) and Represses ERα Messenger RNA and Protein Expression in Breast Cancer Cell Lines , 2007 .

[7]  P. M. Das,et al.  Downregulation of miR-342 is associated with tamoxifen resistant breast tumors , 2010, Molecular Cancer.

[8]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[9]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[10]  B. White,et al.  The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. , 2007, Molecular endocrinology.

[11]  I. Francis,et al.  Reassessment of estrogen receptor expression in human breast cancer cell lines. , 2011, Anticancer research.

[12]  Chen Wu,et al.  An estrogen receptor α suppressor, microRNA‐22, is downregulated in estrogen receptor α‐positive human breast cancer cell lines and clinical samples , 2010, The FEBS journal.

[13]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[14]  Monica Morrow,et al.  Presenting Features of Breast Cancer Differ by Molecular Subtype , 2009, Annals of Surgical Oncology.

[15]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[16]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[17]  S. Cascinu,et al.  HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Børresen-Dale,et al.  Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines , 2009, Oncogene.

[19]  Didier Picard,et al.  miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor α mRNA , 2009, Molecular and Cellular Biology.

[20]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[21]  Hui Wang,et al.  MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. , 2011, Carcinogenesis.